Biomimetic Nanoparticles Enhance Recovery of Movement Disorders in Parkinson’s Disease by Improving Microglial Mitochondrial Homeostasis and Suppressing Neuroinflammation

• Published in: ACS applied materials & interfaces Vol. 17; no. 16; pp. 23536 - 23552
• Main Authors: Li, Liang, Sun, Chunbin, Cai, Shanglin, Hang, Zhongci, Gao, Xiaoyu, Hou, Liangxuan, Li, Luping, Wu, Yawen, Xing, Cencan, Du, Hongwu
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 23.04.2025
• Subjects: Animals; autophagy; bioavailability; Biological and Medical Applications of Materials and Interfaces; Biomimetic Materials - chemistry; Biomimetic Materials - pharmacology; biomimetics; brain; cognitive disorders; Disease Models, Animal; Dopaminergic Neurons - drug effects; fluorescent antibody technique; homeostasis; Homeostasis - drug effects; Humans; inflammation; Inflammation - drug therapy; Male; membrane potential; metformin; Metformin - chemistry; Metformin - pharmacology; Metformin - therapeutic use; Mice; Mice, Inbred C57BL; Microglia - drug effects; Microglia - metabolism; mitochondria; Mitochondria - drug effects; Mitochondria - metabolism; mitochondrial membrane; nanoparticles; Nanoparticles - chemistry; neuroglia; Neuroinflammatory Diseases - drug therapy; oxidative stress; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson Disease - pathology; risk factors; therapeutics; transcriptomics; neuroinflammation; microglia; mitochondrial homeostasis; Parkinson’s disease; bionic nanoparticles

Neuroinflammation is a key risk factor for cognitive impairment, and microglia are the main drivers. Metformin has been shown to suppress inflammation and reduce microglial activation, protecting neurons from damage. However, its clinical efficacy is limited by low bioavailability and metabolic chal...